Immunotherapeutic methods using epitopes of WT-1 and GATA-1 for the treatment of cancers including leukaemia

摘要

Described is a peptide comprising the amino acid sequence RMFPNAPYL or a portion or variant thereof provided that the peptide is not intact human WT-1 polypeptide or a peptide comprising the amino acid sequence CMTWNQMNL or a portion or variant thereof provided that the peptide is not intact human WT-1 polypeptide or a peptide comprising the amino acid sequence HLMPFPGPLL or a portion or variant thereof provided that the peptide is not intact human gata-1 polypeptide, and polynucleotides encoding these peptides. The peptides and polynucleotides are useful as cancer vaccines. The figure shows the killing activity of anti-WT126-34 CTL. T2 is a human cell line with a peptide-loading defect, which is available from the ATCC under Catalogue No CRL 1992. They are loaded with the WT126-34 peptide (RMFPNAPYL) (T2 + WT12) or with E7 control peptide (TLGIVCPI), which is an irrelevant HLA-A2-binding peptide (T2 + E7). K562 is a leukaemia cell line and K562-A2 is the K562 leukaemia cell line transfected with HLA-A0201. The E: T ratio is the effector: target cell ratio. Specific lysis (%) is measured in a standard CTL assay.